Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment.

Bui, TA; Mei, H; Sang, R; Ortega, DG; Deng, W

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment.

Bui, TA Mei, H Sang, R Ortega, DG Deng, W

Permalink

Publisher:: ELSEVIER
Publication Type:: Journal Article
Citation:: EBioMedicine, 2024, 106, pp. 105266
Issue Date:: 2024-08

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Download Published versionAdobe PDF (1.4 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Bui, TA
dc.contributor.author	Mei, H
dc.contributor.author	Sang, R
dc.contributor.author	Ortega, DG
dc.contributor.author	Deng, W https://orcid.org/0000-0002-9413-0978
dc.date.accessioned	2024-09-12T23:22:22Z
dc.date.available	2024-07-22
dc.date.available	2024-09-12T23:22:22Z
dc.date.issued	2024-08
dc.identifier.citation	EBioMedicine, 2024, 106, pp. 105266
dc.identifier.issn	2352-3964
dc.identifier.issn	2352-3964
dc.identifier.uri	http://hdl.handle.net/10453/180801
dc.description.abstract	The Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a ground-breaking immunotherapeutic approach in cancer treatment. To overcome the complexity and high manufacturing cost associated with current ex vivo CAR T cell therapy products, alternative strategies to produce CAR T cells directly in the body have been developed in recent years. These strategies involve the direct infusion of CAR genes via engineered nanocarriers or viral vectors to generate CAR T cells in situ. This review offers a comprehensive overview of recent advancements in the development of T cell-targeted CAR generation in situ. Additionally, it identifies the challenges associated with in vivo CAR T method and potential strategies to overcome these issues.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	ELSEVIER
dc.relation	http://purl.org/au-research/grants/nhmrc/1181889
dc.relation.ispartof	EBioMedicine
dc.relation.isbasedon	10.1016/j.ebiom.2024.105266
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1103 Clinical Sciences, 1117 Public Health and Health Services
dc.subject.classification	3202 Clinical sciences
dc.subject.classification	4202 Epidemiology
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Immunotherapy, Adoptive
dc.subject.mesh	Receptors, Chimeric Antigen
dc.subject.mesh	T-Lymphocytes
dc.subject.mesh	Animals
dc.subject.mesh	Genetic Vectors
dc.subject.mesh	Receptors, Antigen, T-Cell
dc.subject.mesh	T-Lymphocytes
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Receptors, Antigen, T-Cell
dc.subject.mesh	Immunotherapy, Adoptive
dc.subject.mesh	Genetic Vectors
dc.subject.mesh	Receptors, Chimeric Antigen
dc.title	Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment.
dc.type	Journal Article
utslib.citation.volume	106
utslib.location.activity	Netherlands
utslib.for	1103 Clinical Sciences
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.date.updated	2024-09-12T23:22:20Z
dc.rights.holder	© 2024 The Author(s).
pubs.publication-status	Published
pubs.volume	106

Abstract:

The Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a ground-breaking immunotherapeutic approach in cancer treatment. To overcome the complexity and high manufacturing cost associated with current ex vivo CAR T cell therapy products, alternative strategies to produce CAR T cells directly in the body have been developed in recent years. These strategies involve the direct infusion of CAR genes via engineered nanocarriers or viral vectors to generate CAR T cells in situ. This review offers a comprehensive overview of recent advancements in the development of T cell-targeted CAR generation in situ. Additionally, it identifies the challenges associated with in vivo CAR T method and potential strategies to overcome these issues.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/180801